What is the purpose of this trial?
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects)
Ages: 12 years and older
Vertex Pharmaceuticals Incorporated
Start Date: 05/17/2018
End Date: 04/16/2019
Last Updated: 07/10/2018
Study HIC#: 2000022732